Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults (Q39685276)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 2002

Language	Label	Description	Also known as
English	Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults	scientific article published on November 2002

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults (English)

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

0 references

Robert M. Grant

object named as

Robert M Grant

3

0 references

7

object named as

Steven G Deeks

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Christos J Petropoulos

6

object named as

Christos J Petropoulos

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

author name string

Jason D Barbour

1

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Terri Wrin

2

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Jeffrey N Martin

4

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Mark R Segal

5

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

language of work or name

0 references

publication date

1 November 2002

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Journal of Virology

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

76

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

21

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

11104-11112

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

14 September 2017

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

17 June 2018

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

17 June 2018

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=136622

20 August 2018

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation of phenotype evolution of HIV-1 to envelope V2 configuration

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/12368352

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/JVI.76.21.11104-11112.2002

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39685276&oldid=1475661935"